Ultra-fast UPLC-MS/MS approach for the quantification of baricitinib in HLMs matrix: Greenness assessment with application to in vitro and in silico metabolic stability studies

Metabolic stability studies demonstrated moderate baricitinib extraction ratio. Minor adjustments to the pyrrole (88%) and pyrimidine (5%), during drug design, may increase novel derivatives' safety and metabolic stability compared to baricitinib.